tirzepatide 2022 Day 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 and GIP receptor agonist Avg Weight Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for Mounjaro (tirzepatide), a dual GLP-1

It typically begins around week 3 or 4 as doses increase, peaks during weeks 6 through 8, and substantially improves by week 12

MEDICAL Weight Management Achieve lasting results with personalized weight management plans that focus on sustainable lifestyle changes, incorporating advanced treatments like Semaglutide Peptide and Tirzepatide

For weight management without diabetes, the role of metformin is less established and stopping it may be appropriate if tirzepatide alone is achieving your goals

Tip: Take your injection on the same day each week for consistency

NCT07184086 | A Study to See How Metabolism is

That means they were more at risk than the general population